To assess the potential applicability of RIG-I agonist-based therapy to HPV-driven cancers, we first interrogated The Cancer Genome Atlas (TCGA) dataset for RIG-I/DDX58 gene mutations. The gene discussed is RIGI; the disease is cancer.